ELI LILLY & Co
Tremor tracks 45 of its cancer trials. This is a large company with many drugs, so one trial matters less to it, and company-wide signals count for half.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- LLYEli Lilly and Company10Calm
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms
Running, no new patientsPhase 2110 patientsMain results: Mar 20, 2015 - LLYLoxo Oncology, Inc.10Calm
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
FinishedPhase 1/2803 patientsMain results: Jan 27, 2025 - LLYEli Lilly and Company0Calm
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Signing up patientsPhase 3700 patientsMain results: May 2029 - LLYEli Lilly and Company0Calm
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Signing up patientsPhase 31,630 patientsMain results: Nov 2028 - LLYLoxo Oncology, Inc.0Calm
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Signing up patientsPhase 2249 patientsMain results: Jun 2028 - LLYEli Lilly and Company0Calm
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Signing up patientsPhase 31,264 patientsMain results: Nov 2027 - LLYEli Lilly and Company0Calm
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Signing up patientsPhase 3800 patientsMain results: May 2029 - LLYEli Lilly and Company0Calm
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
Signing up patientsPhase 1/227 patientsMain results: Aug 2029 - LLYEli Lilly and Company0Calm
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Signing up patientsPhase 2204 patientsMain results: Dec 2026 - LLYEli Lilly and Company0Calm
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Signing up patientsPhase 2600 patientsMain results: Jan 2029 - LLYEli Lilly and Company0Calm
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Running, no new patientsPhase 3261 patientsMain results: May 1, 2023 - LLYEli Lilly and Company0Calm
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Running, no new patientsPhase 246 patientsMain results: Jan 15, 2025 - LLYEli Lilly and Company0Calm
A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation
Not started yetPhase 250 patientsMain results: Nov 2028 - LLYEli Lilly and Company0Calm
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Running, no new patientsPhase 3669 patientsMain results: Feb 14, 2017 - LLYEli Lilly and Company0Calm
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
Not started yetPhase 2161 patientsMain results: Jul 2028 - LLYEli Lilly and Company0Calm
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Signing up patientsPhase 3450 patientsMain results: Oct 2029 - LLYEli Lilly and Company0Calm
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
Running, no new patientsPhase 3545 patientsMain results: Jan 23, 2019 - LLYEli Lilly and Company0Calm
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
Running, no new patientsPhase 3368 patientsMain results: Feb 8, 2024 - LLYLoxo Oncology, Inc.0Calm
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Running, no new patientsPhase 3282 patientsMain results: Jul 11, 2025 - LLYLoxo Oncology, Inc.0Calm
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
Running, no new patientsPhase 3500 patientsMain results: Nov 2027 - LLYLoxo Oncology, Inc.0Calm
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Signing up patientsPhase 3737 patientsMain results: Oct 2027 - LLYEli Lilly and Company0Calm
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Running, no new patientsPhase 2/3393 patientsMain results: Jan 2, 2024 - LLYEli Lilly and Company0Calm
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
FinishedPhase 1/230 patientsMain results: Jun 14, 2024 - LLYEli Lilly and Company0Calm
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Signing up patientsPhase 2105 patientsMain results: May 2027 - LLYEli Lilly and Company0Calm
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Running, no new patientsPhase 277 patientsMain results: Mar 25, 2021 - LLYEli Lilly and Company0Calm
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Running, no new patientsPhase 2309 patientsMain results: Feb 16, 2018 - LLYEli Lilly and Company0Calm
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
Running, no new patientsPhase 3874 patientsMain results: Jun 24, 2024 - LLYEli Lilly and Company0Calm
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Running, no new patientsPhase 245 patientsMain results: Feb 2027 - LLYEli Lilly and Company0Calm
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Signing up patientsPhase 1/2880 patientsMain results: Jul 2030 - LLYEli Lilly and Company0Calm
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Running, no new patientsPhase 3925 patientsMain results: Feb 15, 2024 - LLYEli Lilly and Company0Calm
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Running, no new patientsPhase 1/2540 patientsMain results: Apr 2027 - LLYLoxo Oncology, Inc.0Calm
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Running, no new patientsPhase 3238 patientsMain results: Aug 29, 2023 - LLYEli Lilly and Company0Calm
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Running, no new patientsPhase 35,637 patientsMain results: Mar 16, 2020 - LLYEli Lilly and Company0Calm
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Running, no new patientsPhase 213 patientsMain results: May 2030 - LLYEli Lilly and Company0Calm
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Running, no new patientsPhase 1/2857 patientsMain results: Feb 14, 2025 - LLYEli Lilly and Company0Calm
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Running, no new patientsPhase 38,000 patientsMain results: Oct 2027 - LLYLoxo Oncology, Inc.0Calm
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Running, no new patientsPhase 3291 patientsMain results: May 22, 2023 - LLYEli Lilly and Company0Calm
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Running, no new patientsPhase 3152 patientsMain results: Jan 12, 2026 - LLYEli Lilly and Company0Calm
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
FinishedPhase 1/247 patientsMain results: Mar 15, 2024 - LLYEli Lilly and Company0Calm
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Running, no new patientsPhase 3453 patientsMain results: Sep 15, 2017 - LLYEli Lilly and Company0Calm
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
Running, no new patientsPhase 3463 patientsMain results: Mar 29, 2019 - LLYEli Lilly and Company0Calm
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
Running, no new patientsPhase 3493 patientsMain results: Jan 31, 2017 - LLYLoxo Oncology, Inc.0Calm
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Running, no new patientsPhase 3600 patientsMain results: Oct 2026 - LLYPOINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company0Calm
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
Running, no new patientsPhase 3455 patientsMain results: Nov 1, 2023 - LLYEli Lilly and Company0Calm
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
Running, no new patientsPhase 1/236 patientsMain results: Nov 8, 2024
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
5 sales (0 not pre-planned) · 0 purchases
- Hakim AnatEVP, GC & Secretary · Nov 2, 2026Sold 5,000 sharesabout $7.0 million · pre-planned
- Jonsson PatrikEVP & President, LLY Int'l · Aug 17, 2026Sold 6,500 sharesabout $7.6 million · pre-planned
- Zakrowski Donald ASVP, Finance, & CAO · Aug 10, 2026Sold 2,000 sharesabout $2.4 million · pre-planned
- Hakim AnatEVP, GC & Secretary · Aug 7, 2026Sold 5,000 sharesabout $6.0 million · pre-planned
- Yuffa IlyaEVP&Pres, LLY USA&Global Capab · Jun 10, 2026Sold 2,500 sharesabout $2.9 million · pre-planned
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.